113 research outputs found
Rassismus und Kulturalismus
Der Arbeitskreis zu "Theorie und Praxis der Interkulturalität" konzentrierte sich im Sommersemester 1997 auf Erscheinungsformen von "Rassismus" und "Kulturalismus" in der Gegenwart. Die meisten der hier versammelten Texte gehen auf Vorträge in diesem Semester zurück.\ud
\ud
\ud
Rassisten glauben gewöhnlich zweierlei: daß es verschiedene Rassen unter den Menschen gibt und man sie auch eindeutig erkennt. Das ist das eine. Der andere Glaubenssatz lautet: Meine Rasse ist die beste.\ud
\ud
\ud
Theoretisch könnte man sich vorstellen, daß jemand den ersten Glaubenssatz annimmt und an den zweiten nicht denkt. Dann wäre das ein rein "wissenschaftliches" Problem und ganz wertfrei. Praktisch ist das aber nicht der Fall, wenn es um gesellschaftliche und politische Fragen geht. Dazu kommt noch ein zweiter Umstand: Man kann vom ersten Glaubenssatz ganz absehen und dennoch eine absolute Überlegenheit der eigenen Art annehmen. Dann wird man nicht mehr von "Rassen" sprechen, sondern von "kulturell Anderen" oder auch von der eigenen "kulturellen" oder "nationalen Identität".\ud
\ud
\ud
Solche "Diskriminierungen", also Ausgrenzungen von etwas, das als Besonderes oder Niedrigeres gegenüber dem Allgemeingültigen oder Höheren gewertet wird, sind das gemeinsame Thema der vorliegenden Beiträge. Es werden aber auch Wege aufgezeigt, menschenverachtenden Ausgrenzungen theoretisch wie praktisch zu begegnen, ohne in die schlechte Alternative zu verfallen, entweder Ghettos in einem "ethnischen Zoo" zu schaffen oder aber eine differenzenlose Einheitsgesellschaft schaffen zu wollen.\ud
\ud
\ud
Das Thema der Transformation von Nationalismus, Rassismus und Kulturalismus behandelt Hakan Gürses. Wenn heute nur mehr selten offen rassistische Thesen öffentlich vertreten werden, so sind doch die Grenzlinien gegenüber den jeweils "Anderen" nicht weniger deutlich: Auch bei "kulturell" Anderen wird regelmäßig eine Rangordnung und natürlich im Vergleich zur eigenen Kultur eine Unterordnung angenommen. Die Popularität dieser Denkweise sieht Gürses begründet in der Gleichzeitigkeit eines elitären Universalismus mit einem partikularistisch-rassistischen Kulturalismus der großen Mittelschicht.\ud
\ud
\ud
Monika Firla behandelt ein heikles Thema der Philosophiegeschichte anhand einer Fallstudie zu Immanuel Kant. Obwohl daraus keinerlei Zweifel an Kants überragender philosophischen Bedeutung abzuleiten ist, ist doch auch nicht zu leugnen, daß er in seinen Vorlesungen rassistische und kulturrassistische Vorurteile nicht nur geteilt, sondern wohl auch befördert hat. Hier drängt sich die allgemeinere Frage auf, ob und wieweit Philosophen sich von diskriminierenden Vorurteilen freimachen können. Vorsichtiges Mißtrauen scheint angebracht.\ud
\ud
\ud
Johann Dvoráks Beitrag befaßt sich mit einer Form von Rassismus und Sexismus, wie sie in der intellektuellen hochkulturellen Szene des Wiener fin de siècle durchaus gesellschaftsfähig waren. Er zeigt das Syndrom bei Chamberlain und Weininger und führt am Beispiel Hofmannsthals aus, wie die nationalistische Denkweise mit Rassismus und Elitendünkel zusammen eine gegen die Arbeiterbewegung gerichtete Ideologie bildete.\ud
\ud
\ud
Vladimir Malachov hat den "neuen Nationalismus" bei deutschsprachigen Philosophen der Gegenwart analysiert. Dabei zeigt sich, etwa in den Arbeiten von Kurt Hübner, daß neuer Wein in Form von komplizierterer Ausdrucksweise doch nur in alte Schläuche gefüllt wird, wenn nicht mehr von einem "Wesen" eines "Volkes", sondern von der "Identität" und dem "Nationalen" die Rede ist. Frühere Chauvinisten drückten sich eindeutiger aus, und Malachov stellt auch dies dar, indem er in sich und untereinander höchst widersprüchliche Versuche vorstellt, das "Wesen" des jeweils eigenen (deutschen, russischen, französischen etc.) und das des anderen Volkes zu beschreiben. Wüßte man nicht um üble Folgen, so wäre die Lektüre amüsant.\ud
\ud
\ud
Ulrike Davy geht konkret der Frage nach, welche Formen das Asylrecht in der Gegenwart angenommen hat. Entscheidend dabei ist, daß die Anerkennung des Flüchtlingsstatus voraussetzt, daß sich der asylgewährende Staat von der Wert- und Staatsordnung des Herkunftslandes distanziert. Somit ist "Empörung" vonnöten, die jedoch wiederum nur bei kultureller Differenz rechtliche Folgen hat.\ud
\ud
\ud
Gero Fischer untersucht Merkmale rassistischer Sprachpraktiken sowohl in humanwissenschaftlichen Disziplinen als auch in der Mediensprache der Gegenwart. Gerade in Debatten um die Multikulturalität in modernen Gesellschaften finden sich dafür bestürzende Belege. Wirklich gefährlich wird diskriminierendes Sprechen - und Darstellen - aber dann, wenn es von denen, die es praktizieren, gar nicht mehr als solches erkannt wird; am Negativbeispiel aus einem Kinderbuch von Thomas Brezina wird dies deutlich.\ud
\ud
\ud
Nadine Hauer hat Aktivitäten gegen Rassismus und Fremdenfeindlichkeit in allen neun österreichischen Bundesländern untersucht und ihr Augenmerk vor allem auf solche Dinge gerichtet, die kaum oder gar keine Bekanntheit erlangen. Sie ist dabei auf wenig Spektakuläres, aber durchaus Eindrucksvolles gestoßen. In ihrem Beitrag schildert sie gelungene und auch mißlungene Projekte von einzelnen wie von Organisationen, Verständnis und Zusammenleben zu fördern und Vorurteile abzubauen
Differences and similarities between spontaneous dissections of the internal carotid artery and the vertebral artery
Background and Purpose—To compare potential risk factors, clinical symptoms, diagnostic delay, and 3-month outcome between spontaneous internal carotid artery dissection (sICAD) and spontaneous vertebral artery dissection (sVAD).
Methods—We compared patients with sICAD (n=668) and sVAD (n=302) treated in 3 university hospitals.
Results—Patients with sICAD were older (46.3±9.6 versus 42.0±10.2 years; P<0.001), more often men (62.7% versus 53.0%; P=0.004), and presented more frequently with tinnitus (10.9% versus 3.4%; P<0.001) and more severe ischemic strokes (median National Institutes of Health Stroke Scale, 10±7.1 versus 5±5.9; P<0.001). Patients with sVAD had more often bilateral dissections (15.2% versus 7.6%; P<0.001) and were more often smokers (36.0% versus 28.7%; P=0.007). Thunderclap headache (9.2% versus 3.6%; P=0.001) and neck pain were more common (65.8% versus 33.5%; P<0.001) in sVAD. Subarachnoid hemorrhage (6.0% versus 0.6%; P<0.001) and ischemic stroke (69.5% versus 52.2%; P<0.001) were more frequent in sVAD. After multivariate analysis, sex difference lost its significance (P=0.21), and all other variables remained significant. Time to diagnosis was similar in sICAD and sVAD and improved between 2001 and 2012 compared with the previous 10-year period (8.0±10.5 days versus 10.7±13.2 days; P=0.004). In sVAD, favorable outcome 3 months after ischemic stroke (modified Rankin Scale, 0–2: 88.8% versus 58.4%; P<0.001), recurrent transient ischemic attack (4.8% versus 1.1%; P=0.001), and recurrent ischemic stroke (2.8% versus 0.7%; P=0.02) within 3 months were more frequent.
Conclusions—sICAD and sVAD patients differ in many aspects. Future studies should perform separate analyses of these 2 entities
EndoVAscular treatment and ThRombolysis for Ischemic Stroke Patients (EVA-TRISP) registry: basis and methodology of a pan-European prospective ischaemic stroke revascularisation treatment registry.
PURPOSE
The Thrombolysis in Ischemic Stroke Patients (TRISP) collaboration was a concerted effort initiated in 2010 with the purpose to address relevant research questions about the effectiveness and safety of intravenous thrombolysis (IVT). The collaboration also aims to prospectively collect data on patients undergoing endovascular treatment (EVT) and hence the name of the collaboration was changed from TRISP to EVA-TRISP. The methodology of the former TRISP registry for patients treated with IVT has already been published. This paper focuses on describing the EVT part of the registry.
PARTICIPANTS
All centres committed to collecting predefined variables on consecutive patients prospectively. We aim for accuracy and completeness of the data and to adapt local databases to investigate novel research questions. Herein, we introduce the methodology of a recently constructed academic investigator-initiated open collaboration EVT registry built as an extension of an existing IVT registry in patients with acute ischaemic stroke (AIS).
FINDINGS TO DATE
Currently, the EVA-TRISP network includes 20 stroke centres with considerable expertise in EVT and maintenance of high-quality hospital-based registries. Following several successful randomised controlled trials (RCTs), many important clinical questions remain unanswered in the (EVT) field and some of them will unlikely be investigated in future RCTs. Prospective registries with high-quality data on EVT-treated patients may help answering some of these unanswered issues, especially on safety and efficacy of EVT in specific patient subgroups.
FUTURE PLANS
This collaborative effort aims at addressing clinically important questions on safety and efficacy of EVT in conditions not covered by RCTs. The TRISP registry generated substantial novel data supporting stroke physicians in their daily decision making considering IVT candidate patients. While providing observational data on EVT in daily clinical practice, our future findings may likewise be hypothesis generating for future research as well as for quality improvement (on EVT). The collaboration welcomes participation of further centres willing to fulfill the commitment and the outlined requirements
a review of methodological design choices
Publisher Copyright: © 2023 Cambridge University Press. All rights reserved.This systematic literature review aimed to provide an overview of the characteristics and methods used in studies applying the Disability-Adjusted Life Years (DALY) concept for infectious diseases within European Union (EU)/European Economic Area (EEA)/European Free Trade Association (EFTA) countries and the United Kingdom. Electronic databases and grey literature were searched for articles reporting the assessment of DALY and its components. We considered studies in which researchers performed DALY calculations using primary epidemiological data input sources. We screened 3,053 studies of which 2,948 were excluded and 105 studies met our inclusion criteria. Of these studies, 22 were multi-country and 83 were single-country studies, of which 46 were from the Netherlands. Food- and water-borne diseases were the most frequently studied infectious diseases. Between 2015 and 2022, the number of burden of infectious disease studies was 1.6 times higher compared to that published between 2000 and 2014. Almost all studies (97%) estimated DALYs based on the incidence- and pathogen-based approach and without social weighting functions; however, there was less methodological consensus with regards to the disability weights and life tables that were applied. The number of burden of infectious disease studies undertaken across Europe has increased over time. Development and use of guidelines will promote performing burden of infectious disease studies and facilitate comparability of the results.publishersversionepub_ahead_of_prin
Multiple Myeloma Treatment in Real-world Clinical Practice : Results of a Prospective, Multinational, Noninterventional Study
Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: M.M. has received personal fees from Janssen, Celgene, Amgen, Bristol-Myers Squibb, Sanofi, Novartis, and Takeda and grants from Janssen and Sanofi during the conduct of the study. E.T. has received grants from Janssen and personal fees from Janssen and Takeda during the conduct of the study, and grants from Amgen, Celgene/Genesis, personal fees from Amgen, Celgene/Genesis, Bristol-Myers Squibb, Novartis, and Glaxo-Smith Kline outside the submitted work. M.V.M. has received personal fees from Janssen, Celgene, Amgen, and Takeda outside the submitted work. M.C. reports honoraria from Janssen, outside the submitted work. M. B. reports grants from Janssen Cilag during the conduct of the study. M.D. has received honoraria for participation on advisory boards for Janssen, Celgene, Takeda, Amgen, and Novartis. H.S. has received honoraria from Janssen-Cilag, Celgene, Amgen, Bristol-Myers Squibb, Novartis, and Takeda outside the submitted work. V.P. reports personal fees from Janssen during the conduct of the study and grants, personal fees, and nonfinancial support from Amgen, grants and personal fees from Sanofi, and personal fees from Takeda outside the submitted work. W.W. has received personal fees and grants from Amgen, Celgene, Novartis, Roche, Takeda, Gilead, and Janssen and nonfinancial support from Roche outside the submitted work. J.S. reports grants and nonfinancial support from Janssen Pharmaceutical during the conduct of the study. V.L. reports funding from Janssen Global Services LLC during the conduct of the study and study support from Janssen-Cilag and Pharmion outside the submitted work. A.P. reports employment and shareholding of Janssen (Johnson & Johnson) during the conduct of the study. C.C. reports employment at Janssen-Cilag during the conduct of the study. C.F. reports employment at Janssen Research and Development during the conduct of the study. F.T.B. reports employment at Janssen-Cilag during the conduct of the study. The remaining authors have stated that they have no conflicts of interest. Publisher Copyright: © 2018 The AuthorsMultiple myeloma (MM) remains an incurable disease, with little information available on its management in real-world clinical practice. The results of the present prospective, noninterventional observational study revealed great diversity in the treatment regimens used to treat MM. Our results also provide data to inform health economic, pharmacoepidemiologic, and outcomes research, providing a framework for the design of protocols to improve the outcomes of patients with MM. Background: The present prospective, multinational, noninterventional study aimed to document and describe real-world treatment regimens and disease progression in multiple myeloma (MM) patients. Patients and Methods: Adult patients initiating any new MM therapy from October 2010 to October 2012 were eligible. A multistage patient/site recruitment model was applied to minimize the selection bias; enrollment was stratified by country, region, and practice type. The patient medical and disease features, treatment history, and remission status were recorded at baseline, and prospective data on treatment, efficacy, and safety were collected electronically every 3 months. Results: A total of 2358 patients were enrolled. Of these patients, 775 and 1583 did and did not undergo stem cell transplantation (SCT) at any time during treatment, respectively. Of the patients in the SCT and non-SCT groups, 49%, 21%, 14%, and 15% and 57%, 20%, 12% and 10% were enrolled at treatment line 1, 2, 3, and ≥ 4, respectively. In the SCT and non-SCT groups, 45% and 54% of the patients had received bortezomib-based therapy without thalidomide/lenalidomide, 12% and 18% had received thalidomide/lenalidomide-based therapy without bortezomib, and 30% and 4% had received bortezomib plus thalidomide/lenalidomide-based therapy as frontline treatment, respectively. The corresponding proportions of SCT and non-SCT patients in lines 2, 3, and ≥ 4 were 45% and 37%, 30% and 37%, and 12% and 3%, 33% and 27%, 35% and 32%, and 8% and 2%, and 27% and 27%, 27% and 23%, and 6% and 4%, respectively. In the SCT and non-SCT patients, the overall response rate was 86% to 97% and 64% to 85% in line 1, 74% to 78% and 59% to 68% in line 2, 55% to 83% and 48% to 60% in line 3, and 49% to 65% and 36% and 45% in line 4, respectively, for regimens that included bortezomib and/or thalidomide/lenalidomide. Conclusion: The results of our prospective study have revealed great diversity in the treatment regimens used to manage MM in real-life practice. This diversity was linked to factors such as novel agent accessibility and evolving treatment recommendations. Our results provide insight into associated clinical benefits.publishersversionPeer reviewe
Evaluation of oxidative stress parameters and metabolic activities of nurses working day and night shifts
Burden of infectious disease studies in Europe and the United Kingdom: a review of methodological design choices.
This systematic literature review aimed to provide an overview of the characteristics and methods used in studies applying the disability-adjusted life years (DALY) concept for infectious diseases within European Union (EU)/European Economic Area (EEA)/European Free Trade Association (EFTA) countries and the United Kingdom. Electronic databases and grey literature were searched for articles reporting the assessment of DALY and its components. We considered studies in which researchers performed DALY calculations using primary epidemiological data input sources. We screened 3053 studies of which 2948 were excluded and 105 studies met our inclusion criteria. Of these studies, 22 were multi-country and 83 were single-country studies, of which 46 were from the Netherlands. Food- and water-borne diseases were the most frequently studied infectious diseases. Between 2015 and 2022, the number of burden of infectious disease studies was 1.6 times higher compared to that published between 2000 and 2014. Almost all studies (97%) estimated DALYs based on the incidence- and pathogen-based approach and without social weighting functions; however, there was less methodological consensus with regards to the disability weights and life tables that were applied. The number of burden of infectious disease studies undertaken across Europe has increased over time. Development and use of guidelines will promote performing burden of infectious disease studies and facilitate comparability of the results
Recommended from our members
Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study
Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat
Recommended from our members
Correction to: Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study
The original version of this article unfortunately contained a mistake
Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study
Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat
- …